MAPT and Alzheimer disease: The current gold standard of diagnosis, besides postmortem pathological evaluation of AD, is based on in vivo evidence of increased Aβ and Tau brain burden, measured by either positron emission tomography (PET) scans and/or cerebrospinal fluid (CSF) studies (10).